Lilly 4Q Revenues: $5.1 billion (-12%) 4Q Earnings: $428.5 (-41%) FY Revenues: $19.6 billion (-15%) FY Earnings: $2.4 billion (-49%) Comments: Results were impacted by U.S. patent expirations for Cymbalta (-58% to $367 million in 4Q14) and Evista (-74% to $72 million in 4Q14) and the unfavorable impact of foreign exchange rates. Alimta sales were flat at $725 million in the quarter. Humalog sales were $729 million (-1%). Cialis sales were up 6% to $622 million. Humulin sales were $396 milli...